Skip to main content

Breast Cancer

Breast Cancer, FDA Approvals, In the News, Oncology

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, In the News, Oncology

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

Breast Cancer, Oncology

Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer

Breast Cancer, Oncology

First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer

Breast Cancer, Oncology

Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is in the Details

Breast Cancer, Oncology

CAR T-Cell Therapy Yields Impressive Responses in Aggressive Non-Hodgkin Lymphoma

Breast Cancer, Oncology

Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer, Oncology

Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer

Breast Cancer, Oncology

Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancer

Breast Cancer, Oncology

Review of Ribociclib for Advanced Hormone Receptor–Positive Breast Cancer

Lowell L Hart, MD

Page 2 of 3
Results 11 - 20 of 30